Patients with mesothelioma, a disease of the lung lining caused by exposure to asbestos, may someday benefit from a new 3D PET measure that helps accurately and quickly measure response to chemotherapy, according to a study published in the Journal of Nuclear Medicine.
Patients with mesothelioma, a disease of the lung lining caused by exposure to asbestos, may someday benefit from a new 3D PET measure that helps accurately and quickly measure response to chemotherapy, according to a study published in the Journal of Nuclear Medicine.
An estimated 3000 malignant mesothelioma cancer cases are reported every year in the U.S. The most common type, pleural mesothelioma, represents about three-fourths of cases overall.
Measuring response to therapy with CT has proven more challenging for this cancer than other types of tumors. Criteria from the Response Evaluation Criteria in Solid Tumors (RECIST) trial have been adapted for mesothelioma, but measurement is difficult and time-consuming. It may be possible to measure response only after several treatments.
Volume-based measurement of tumor with FDG-PET is helpful in predicting response after just one round of chemotherapy, according to a study published in September by researchers at Sir Charles Gairdner Hospital's PET Center in Western Australia and other area research facilities (JNM 2007:48:1449-1458).
The researchers developed software to assess total glycolytic volume (TGV), a 3D measure that reflects tumor volume and metabolic activity on FDG-PET scans. The value of both TGV and maximum standardized uptake value (SUVmax) on PET were compared with the CT measures, using RECIST criteria.
The 23 patients involved in the study were set to undergo chemotherapy with cisplatin and gemcitabine. PET was performed before and after the first cycle of treatment, and contrast-enhanced thoracic and upper abdominal CT scans were done at baseline and after every treatment.
CT results were used to make decisions about therapy, but PET assessments did not affect treatment. Based on the imaging studies, radiologists determined whether there had been a complete response, partial response, or stable disease.
The results indicated TGV is very useful for measuring effect on tumors after just one round of chemotherapy. It proved more accurate than both SUVmax and CT measures for predicting survival.
"Metabolic imaging has the potential to improve the care of patients receiving chemotherapy for mesothelioma by the early identification of responding patients," the authors said. "This technology may also be useful in the assessment of new systemic treatments for mesothelioma."
For more information from the Diagnostic Imaging archives:
SUVs earn cheers for research but jeers for routine clinical use
PET/CT proves superior for staging cancers
Chest physicians group opposes CT lung cancer screening
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.